Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The restless legs syndrome.

Claudia Trenkwalder1, Walter Paulus, Arthur S Walters

  • 1Paracelsus Elena Klinik, Centre of Parkinsonism and Movement Disorders, Kassel, Germany. ctrenkwalder@gmx.de

The Lancet. Neurology
|July 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal dynamics of cognitive functioning in people with Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

MDS Global Survey on Work Environment, Career Advancement, and Work-Life Balance in Movement Disorders Professionals: Gender and Regional Patterns.

Movement disorders clinical practice·2026
Same author

Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders.

medRxiv : the preprint server for health sciences·2026
Same author

How many do we miss? - Evaluation of age at onset and family history as selection criteria for genetic testing in Parkinson's disease.

medRxiv : the preprint server for health sciences·2026
Same author

From cigarettes to symptoms: the association between smoking and depression in the German National Cohort (NAKO).

BMC public health·2025
Same author

Further evidence that painful and painless restless legs syndrome are contrasting phenotypes: a study of adult twins and their families.

Sleep medicine·2025
Same journal

Resolution of expression of concern-Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

The Lancet. Neurology·2026
Same journal

UCL Queen Square Institute of Neurology: 75 years of innovation.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 631.

The Lancet. Neurology·2026
Same journal

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2025; 24: 740-52.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 357-67.

The Lancet. Neurology·2026
See all related articles

Restless Legs Syndrome (RLS) is a common neurological disorder with genetic and symptomatic causes. Treatment focuses on dopaminergic agents and iron metabolism for moderate to severe cases.

Area of Science:

  • Neurology
  • Genetics
  • Pharmacology

Background:

  • Restless Legs Syndrome (RLS) is a prevalent neurological disorder.
  • It presents as idiopathic (genetic/unknown origin) or symptomatic forms.
  • Symptomatic RLS is linked to pregnancy, uraemia, iron deficiency, and other conditions.

Purpose of the Study:

  • To summarize the current understanding of Restless Legs Syndrome.
  • To outline the genetic basis and prevalence of RLS.
  • To review the pathophysiology and treatment options for RLS.

Main Methods:

  • Literature review of RLS studies.
  • Analysis of genetic loci associated with hereditary RLS.
  • Overview of pharmacological treatments and their monitoring.

Related Experiment Videos

Main Results:

  • Three gene loci for hereditary RLS identified on chromosomes 12, 14, and 9.
  • Prevalence ranges from 3% to 9%, increasing with age and higher in women.
  • Dopaminergic system and iron metabolism are key to RLS pathophysiology and treatment.

Conclusions:

  • Dopaminergic therapy (levodopa, dopamine agonists) is primary for idiopathic RLS.
  • Long-term treatment requires monitoring for augmentation and rebound.
  • Alternative treatments include opioids, gabapentin, and benzodiazepines for RLS management.